Implementation of biosecurity on equestrian premises: A narrative overview.

Vet J. February 2023;292(0):105950.

C R Crew¹, M L Brennan², J L Ireland³

¹ Department of Health and Social Care, 39 Victoria Street, London SW1H 0EU, UK; The Royal Veterinary College, Hawkshead Lane, Hatﬁeld, Hertfordshire AL9 7TA, UK.; ² School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington Campus, Leicestershire LE12 5RD, UK.; ³ Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, The University of Liverpool, Leahurst Campus, Neston, Cheshire CH64 7TE, UK. Electronic address: Joanne.Ireland@liverpool.ac.uk.

Abstract

Biosecurity measures are designed to prevent the introduction and spread of pathogens, and play a vital role in the equine industry, controlling endemic diseases and reducing the threat of exotic disease incursion. Equestrian premises differ with respect to disease risks, biosecurity requirements and available facilities. This narrative review summarises reported frequency of implementation for selected biosecurity measures, as well as evidence relating to potential barriers to implementation of biosecurity on equestrian premises. Possible opportunities for improvement in the adoption of equine biosecurity measures are also discussed.

Keywords

Equine; Infection control; Quarantine; Transmission; Vaccination;

Article Tools:

Medline

Email to me

Archives Highlights:

Recovery of ambulation in small, nonbrachycephalic dogs after conservative management of acute thoracolumbar disk extrusion.
Forty-nine of fifty-one (96%) of deep pain-positive and 10/21 (48%) of deep pain-negative dogs recovered ambulation within the 12-week period. The median time to ambulation was 11 and 25 days for deep pain-positive and -negative dogs, respectively. Reduction in spinal cord compression varied among individuals from minimal to complete and apparently was unrelated to the recovery of ambulation.

[Disease Caused by Filoviruses: An Update].
The Marburg and Ebola viruses belong to the Filoviridae family and are known to cause emerging zoonotic diseases. These viruses have a high case fatality rate and are easily transmissible from person to person, which makes them capable of triggering outbreaks, including in non-endemic regions, and are also considered agents of bioterrorism. This review aims to improve clinical knowledge and the approach to suspected cases of FD. Improved surveillance and preparedness for potential global outbreaks are essential measures to effectively respond to these public health threats and to ensure that healthcare professionals are well-informed and prepared to deal with these diseases.

Effective treatment with afoxolaner (NexGard) of Trixacarus caviae in a pet guinea pig.
The animal was treated with a single oral dose of 2.50 mg/kg afoxolaner, and the lesions, presence/absence of mites, and intensity of pruritus were evaluated periodically until 2 months post-treatment. A week after the medication, the lesions were milder, but pruritus was still present and was attributed to the healing process. Further examinations showed significant improvement with the complete remission of clinical signs and no mites at the microscopic examination after 4 weeks.

Indications for Radiation Therapy in Veterinary Medicine
This article highlights some of the essential elements for clinical decision making in veterinary radiation oncology, with case examples to give general practitioners a better understanding of what types of cases may be appropriate for radiation therapy.

The 4 prokinetic drugs metoclopramide, cisapride, pyridostigmine, and capromorelin do not increase fecal output or food intake in healthy New Zealand rabbits (Oryctolagus cuniculus).
Every day, rabbits produced a median of 75 g (range, 9 to 145 g) of feces, 226 fecal pellets (range, 12 to 412 pellets), and 151 mL (range, 5 to 420 mL) of urine. Metoclopramide, cisapride, pyridostigmine, and capromorelin had no effect on fecal production (both weight and number of pellets), food intake, urine production, or water intake compared to placebo at 24, 48, or 72 hours after administration.